WEST PALM BEACH, FL · ADULT DEPRESSION TREATMENT
Depression Treatment in West Palm Beach
Adult Outpatient Depression Treatment in West Palm Beach
Depression treatment at Mental Health West Palm Beach – Trustpsychiatry — DSM-5-TR · PHQ-9 measurement-based care · SSRI/SNRI first-line with augmentation when partial response shows up at week four.
- ✓SSRI/SNRI first-line for major depressive disorder
- ✓4–8 week response window at therapeutic dose
- ✓Augmentation (lithium, atypicals, bupropion, T3) for partial response
- ✓Combined medication management + supportive psychotherapy in one chart
Serving West Palm Beach · Lake Worth · Wellington · Palm Beach · Greenacres · Riviera Beach · Statewide Florida telepsychiatry
ACCESS & AVAILABILITY
✓Same-day when available · ✓Evening hours · ✓Weekend by appointment · ✓Statewide Florida telepsychiatry
Insurance benefits verified before your first visit at Mental Health West Palm Beach – Trustpsychiatry.
WHAT TO EXPECT
What a depression intake actually looks like at Mental Health West Palm Beach – Trustpsychiatry.
Four anchors define the first visit and the months that follow. Depression treatment is patient and methodical — the structure earns its keep because SSRIs need a fair window at a fair dose before any decision gets made.
| Anchor | Duration | Detail |
|---|---|---|
| Initial evaluation | 30–60 Min | DSM-5-TR depression assessment with PHQ-9 baseline, bipolar-spectrum screen, prior-trial history, and collateral when useful. |
| Med trial cadence | 20–30 Min | Follow-ups every 2–4 weeks during titration, stretching to 4–6 weeks for the adequate-trial reassessment. |
| Response window | 4–8 weeks | Full SSRI response runs 4–8 weeks at therapeutic dose. Partial response at week four triggers the augmentation conversation. |
| Continuation phase | 6–12 mo | Six to twelve months at the therapeutic dose post-remission, longer for recurrent presentations. Discontinuation is tapered, never abrupt. |
WHAT WE DELIVER
Outpatient depression care across SSRIs, SNRIs, atypicals, and augmentation.
Depression care here is built around six clinical anchors. DSM-5-TR criteria drive the diagnosis; PHQ-9 measurement-based care drives the cadence. Medication management and supportive psychotherapy live in the same chart so the plan moves as one piece.
SSRIs — first-line for MDD and PDD
Sertraline, escitalopram, and fluoxetine carry the bulk of first-line decisions for major depressive disorder and persistent depressive disorder. Side-effect profile matched to the patient, not the chart order.
SNRIs — when serotonin alone isn’t enough
Venlafaxine and duloxetine bring norepinephrine into the picture for adults with prominent fatigue, somatic pain, or partial response on a serotonin-only agent.
Atypical antidepressants
Bupropion for low-energy, low-motivation, weight-neutral presentations. Mirtazapine for insomnia-dominant depression with appetite loss. Picked against the symptom pattern, not by default.
Augmentation strategies
Lithium, atypical antipsychotics (aripiprazole), bupropion add-on, and thyroid T3 augmentation for partial-response cases and treatment-resistant depression. STAR*D evidence base, applied per case.
Co-occurring care in one chart
Anxiety, ADHD, and substance use disorder commonly co-travel with depression. Both managed by the same prescriber in the same chart — the plans talk to each other instead of around each other.
Medication + supportive psychotherapy
Combined medication management and supportive psychotherapy in the same visit when clinically indicated. The medication moves the chemistry; the psychotherapy moves the behavior. Together they outperform either alone.
WHO WE SERVE
When outpatient depression treatment is the right fit for the adult in your chair.
Outpatient psychiatry works for depression when safety is stable, the medical picture is manageable, and the case fits an office-based cadence. The adults for whom that combination lands are not a single archetype.
| Archetype | Why outpatient fits |
|---|---|
| The first-time-treated adult | Symptoms have lasted weeks, function is bending, and SSRI/SNRI first-line is the clean start. |
| The partial-response adult on SSRI | Week-four PHQ-9 drop is real but not enough. Augmentation or switch deserves a careful look. |
| The recurrent depression patient | A prior episode resolved, treatment came off, and the pattern is back. Maintenance horizon needs to widen. |
| The treatment-resistant depression case | Two adequate trials have not delivered remission. STAR*D-style sequencing with augmentation is on the table. |
| The co-occurring depression+anxiety patient | Both conditions in the same chart, one prescriber, one plan that keeps the agents from working at cross-purposes. |
| The patient with depression after SUD recovery | Substance use stabilized; the depression underneath surfaces and now needs its own pharmacologic answer. |
OUR PROCESS
How depression care unfolds at Trust Psychiatry.
Three steps from first call to ongoing care. PHQ-9 numbers run alongside the conversation so the change in the chart matches the change in the chair. Adequate-trial decisions need fair data, not impressions.
60-Minute evaluation with PHQ-9 baseline
DSM-5-TR assessment, PHQ-9 baseline, bipolar-spectrum screen, prior medication history, sleep, alcohol, thyroid review. The intake earns a clean diagnostic picture, not a rushed prescription.
Treatment trial + cadence-based reassessment
First-line SSRI, SNRI, or bupropion matched to the pattern. Follow-ups every two to four weeks during titration. Adequate-trial reassessment at four to six weeks — adjust, switch, or augment on real PHQ-9 deltas.
Ongoing measurement-based care
Stable maintenance every one to three months once response is solid. Six to twelve months at therapeutic dose post-remission for a first episode; longer for recurrent presentations. Discontinuation tapered with the prescriber.
WHAT THE EVIDENCE SAYS
Three things worth knowing about depression treatment.
APA Clinical Practice Guideline, NIMH STAR*D trial data, and decades of meta-analytic work on SSRI efficacy converge on the same picture: dose and duration earn the win, measurement-based care shortens the path, and partial response demands sequencing instead of waiting it out.
“The NIMH STAR*D trial showed roughly one in three adults remit on the first antidepressant — and that cumulative remission climbs with each carefully sequenced step. The hard work is the sequencing, not the first prescription.”
Mechanism: the STAR*D landmark trial established the evidence base for sequenced treatment in major depressive disorder — switch or augment, do not stall.
“Meta-analyses across thousands of randomised SSRI trials confirm a meaningful efficacy edge over placebo for moderate-to-severe major depressive disorder. The biggest predictor of failure is a dose too low and a trial too short.”
Mechanism: SSRIs need four to six weeks at a therapeutic dose before any trial gets called a failure — undertreatment masquerades as treatment resistance.
“Measurement-based care — PHQ-9 at every visit, with thresholds that trigger adjust, switch, or augment — shortens time-to-remission compared with usual care that runs on impressions alone.”
Mechanism: PHQ-9 deltas surface partial response at week four, before the patient or the prescriber can rationalise the data away.
Ready to put the evidence to work? Schedule a depression evaluation →
SCOPE — STRAIGHT
What Trust Psychiatry delivers — and what falls outside outpatient scope.
Trust Psychiatry delivers adult outpatient depression care for major depressive disorder, persistent depressive disorder, and treatment-resistant presentations — DSM-5-TR diagnosis, PHQ-9 measurement-based cadence, SSRI/SNRI first-line with augmentation when partial response shows up, and supportive psychotherapy combined in the same chart. ECT, TMS, and ketamine/esketamine sit outside outpatient psychiatric scope here.
The flip side matters too — pediatric psychiatry, inpatient psychiatric care, and severe postpartum depression with acute safety risk also fall outside outpatient scope. When the assessment points to a higher level of care, the recommendation goes there. The job at intake is to match the case to the right level, not to push every adult through the same door.
Other Services at Trust Psychiatry
More services at Mental Health West Palm Beach – Trustpsychiatry
Medication Management · Psychiatric Evaluation · Telepsychiatry Florida · Prescription Refills · MAT/Suboxone · Supportive Psychotherapy · TOVA Cognitive Testing
YOUR PRESCRIBER
Who you’ll see for outpatient depression care.
Josie Desmarais, PMHNP-BC, ANCC board-certified, sole prescriber at Mental Health West Palm Beach – Trustpsychiatry. 16+ years at Bay Pines VA Healthcare System (2007–2023) where adult depression with co-occurring conditions was the daily caseload. PHQ-9-anchored cadence, STAR*D sequencing framework, augmentation strategies on the table when partial response shows up.
Read Josie’s full bio →OUR LOCATION
Visit us in Haverhill, West Palm Beach.
Off I-95 at Belvedere Rd · 7 minutes from Palm Beach International Airport (PBI) · In Haverhill, West Palm Beach FL 33415
Adults across Lake Worth · Wellington · Palm Beach · Greenacres · Riviera Beach · statewide Florida via secure telepsychiatry.
Trust Psychiatry & Wellness
4500 Belvedere Rd, Suite D
West Palm Beach, FL 33415
Hours
Mon–Fri: 9:00 AM – 5:00 PM
Sat: By appointment
Sun: Closed
Related Conditions
Conditions we treat alongside depression
Anxiety Treatment · ADHD Treatment · PTSD Treatment · OCD Treatment · Bipolar Disorder Treatment · Mood Disorder Treatment · Insomnia Treatment · Substance Use Disorder · CBT Therapy · DBT Therapy · ACT Therapy · Mindfulness Therapy
FREQUENTLY ASKED
Common questions about outpatient depression treatment.
How long until SSRIs start working? ▸
Most adults see meaningful improvement at four to eight weeks on a therapeutic SSRI dose. Sleep and appetite often shift in the first two weeks; mood and interest lag a little behind. PHQ-9 at every visit tracks the curve so the response is measured, not guessed at.
What if my first medication doesn’t help? ▸
Two clean paths. A switch to another first-line agent (a different SSRI, an SNRI, or bupropion). Or augmentation — lithium, an atypical antipsychotic like aripiprazole, bupropion add-on to an SSRI, or thyroid T3. STAR*D data shows cumulative remission climbs with each carefully sequenced step.
Will I be on antidepressants forever? ▸
For a first depressive episode, most adults stay on medication six to twelve months past remission before a structured taper. For recurrent episodes, the maintenance horizon widens — sometimes years. Discontinuation is patient-driven and tapered with the prescriber, never stopped abruptly.
Can I drink alcohol on SSRIs? ▸
Light, infrequent use is generally tolerated for most adults on an SSRI, but heavy or daily use blunts response and worsens depression on its own. The honest answer in the room covers the patient’s actual pattern and the specific medication. For patients with co-occurring alcohol use disorder, the SUD plan and the depression plan live in the same chart.
What’s the difference between SSRIs and SNRIs? ▸
SSRIs (sertraline, escitalopram, fluoxetine) act on serotonin alone. SNRIs (venlafaxine, duloxetine) act on serotonin and norepinephrine. SNRIs often earn first-line consideration when fatigue, low energy, or somatic pain dominates the presentation, or when an SSRI brought partial response.
What about side effects? ▸
Common SSRI side effects (GI upset, sleep changes, sexual side effects) are reviewed at every titration visit. Most settle within the first two to three weeks. When they don’t, the choice is a dose change, a switch, or a side-effect-targeted strategy. The FDA boxed warning on antidepressants for adults under 25 means closer suicidality monitoring during initiation and dose changes — standard-of-care, surfaced openly.
Can I do telepsychiatry for depression? ▸
Yes. Adult depression med-management runs well on secure telepsychiatry for Florida residents — intake, titration visits, and stable maintenance all on video. In-office is available when preferred or clinically indicated. The intake call confirms the right format.
What about ketamine or esketamine for treatment-resistant depression? ▸
Ketamine and esketamine (Spravato) sit outside outpatient psychiatric scope at Mental Health West Palm Beach – Trustpsychiatry. For treatment-resistant depression where two adequate trials have not delivered remission, the in-house path runs through STAR*D-style sequencing and augmentation (lithium, atypicals, T3, vortioxetine switch). TMS and ECT also live outside this practice.
READY WHEN YOU ARE
Start with the depression evaluation.
In-network with twelve major Florida plans. DSM-5-TR depression evaluation, PHQ-9 measurement-based cadence, SSRI/SNRI first-line with augmentation when partial response shows up, supportive psychotherapy combined in the same chart.
If you are in crisis call 988 or 911.